Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Market growth in the global thrombus treatment sector is significantly influenced by the introduction of new products, a process that involves major players investing in research and development (R&D). These key companies are consistently dedicating resources to create innovative and more effective products. Once these products undergo extensive R&D efforts and rigorous testing, they receive approval from regulatory bodies. A prime example of this is Johnson & Johnson (US), which, in December 2021, gained approval from the FDA (Food and Drug Administration) for XARELTO (rivaroxaban), a medication designed to treat blood clots in pediatric patients.
In addition to developing new treatment solutions, companies are also working on diagnostic products that can provide more accurate diagnoses of thrombosis. Sysmex Corporation (Japan), for instance, launched Automated Blood Coagulation Analyzers in July 2020. These analyzers are designed to accurately detect blood coagulation parameters, including molecular markers, all in a single device.
Furthermore, major players are expanding their capabilities by acquiring other companies in the field. An illustration of this is the acquisition made by Abbott Laboratories (US) in September 2021 when they acquired Walk Vascular, LLC (US). This strategic move aimed to enhance Abbott Laboratories' surgical capabilities, particularly in thrombectomy—a surgical procedure used to remove blood clots. Such initiatives undertaken by key players not only contribute to the development of novel and more efficient products but are also anticipated to drive further growth in the thrombus treatment market.
The cornerstone of market growth lies in the continual efforts of major players to innovate and introduce new products. These endeavors are often fueled by substantial investments in research and development. The goal is to bring forth treatments that are not only effective but also address specific needs within the healthcare landscape. Johnson & Johnson's achievement in gaining FDA approval for XARELTO, particularly for treating blood clots in pediatric patients, exemplifies the successful outcome of such dedicated R&D initiatives.
Beyond therapeutic interventions, there is a parallel focus on diagnostic tools to enhance the accuracy of thrombosis diagnoses. Sysmex Corporation's Automated Blood Coagulation Analyzers, introduced in July 2020, mark a notable advancement in this regard. The analyzers offer a comprehensive approach by accurately detecting various blood coagulation parameters and molecular markers. This innovation is poised to improve the diagnostic process and subsequently contribute to more targeted and effective treatment strategies.
The market landscape is further shaped by strategic acquisitions, as demonstrated by Abbott Laboratories' acquisition of Walk Vascular, LLC. By bringing additional capabilities, particularly in the domain of thrombectomy, Abbott Laboratories aims to strengthen its position in providing comprehensive solutions for the removal of blood clots. This strategic move not only broadens the scope of their offerings but also signifies a commitment to advancing surgical capabilities, which is crucial in the treatment of thrombus-related conditions.
These collective initiatives by major players in the thrombus treatment market are positioned to usher in a new era of more efficient and diversified products. The emphasis on innovation, both in therapeutic and diagnostic realms, aligns with the evolving needs of patients and healthcare professionals. As companies continue to invest in R&D, gain regulatory approvals, and expand their capabilities through strategic acquisitions, the thrombus treatment market is expected to witness sustained growth. These developments underscore the industry's commitment to addressing thrombus-related conditions comprehensively, paving the way for improved patient outcomes and advancements in the broader field of healthcare.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Segment Outlook | Type, Treatment, and Region |
Thrombus Treatment Market Highlights:
Global Thrombus Treatment Market Overview
Thrombus Treatment Market Size was valued at USD 39.43 Billion in 2023. The Global Thrombus Treatment industry is projected to grow from USD 40.27 Billion in 2024 to USD 70.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.57% during the forecast period (2024 - 2032).
The factors influencing the market growth are increasing incidence of trauma cases and rising adoption of sedentary lifestyle are bolstering the market growth.
Thrombus Treatment Market Trends
- Increasing incidence of trauma cases fuels market growth
Trauma is considered as one of the most common causes for the formation of thrombus in the lower extremities. When any blood vessels get damages, the surround blood thickens and forms a clot. Hence, blood vessel damage due to trauma can cause the formation of a thrombus. The increases number trauma cases, especially road accidents have led to the increase in demand for thrombus treatment. According to the WHO in June 2022, around 1.3 million people lose their lives due to road accidents globally. Additionally, 20-30 trillion people suffer non-fatal injuries per year. Over 90% of such fatalities occur in low- and middle-income countries which is expected to drive the market of thrombus treatment significantly in those countries with a significant growth rate.
Additionally, there were 178 million new fracture cases registered in 2019 globally which had increased by 33.4% since 1990. The total prevalence of acute and long-term fracture symptoms had reached 455 million in 2910 with an increase of 67.5% since 1990. Fracture is another common cause for thrombosis. Hence, the increasing incidence of trauma cases is driving market demand for the Thrombus Treatment.
Thrombus Treatment Market Segment Insights
Thrombus Treatment Type Insights
The market segments of thrombus treatment, based on type, includes atrial thrombus and venous thrombus. The atrial thrombus bifurcated into right atrial thrombus and left atrial thrombus. Venous thrombus held the largest market share and contributed USD 22.58 billion in 2021 owing to the interaction between obesity and other risk factors doubles the risk of venous thrombus. The World Obesity Atlas 2022 stated that 1 billion people globally i.e., 1 in 5 women and 1 in 7 men will have diabetes by 2030. Therefore, the increase in obesity in the coming years will lead to venous thrombosis, fueling the venous thrombosis segment market.
Thrombus Treatment Treatment Insights
The Thrombus Treatment Market data has been segmented, based on treatment, by medical therapy, surgery, and others. The medical therapy segment has been segmented into antiplatelets, anticoagulants, and thrombolytics. Medical therapy held the largest market share and contributed USD 34.36 billion in 2021 and the surgery anticipated to register the highest CAGR of 7.78% from 2024 to 2032. The most common antiplatelets used to treat thrombus include acetylsalicylic acid (ASA), clopidogrel, prasugrel, and ticagrelor. Acetylsalicylic acid includes aspirin, which is effective in treating thrombosis.
December 2021, Johnson & Johnson's (US) subsidiary Janssen Pharmaceutical Companies (Belgium) announced that the US Food and Drug Administration (FDA) had approved its two paediatric indications for XARELTO.
Figure 2: Thrombus Treatment Market, by Treatment, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Thrombus Treatment Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America held the largest market share and contributed USD 16.19 billion in 2021 owing to developed healthcare infrastructure, research grants for producing safe and effective thrombus treatment, the growing aged and obese population in the region. For instance, according to the World Health Organization (WHO) 2021, the North America population over 80 years will triple from 143 million in 2019 to 426 million in 2050. Therefore, the growing aged and obese population supports the market growth of thrombus treatment.
Further, the major countries studied are: The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: THROMBUS TREATMENT MARKET BY REGION 2022 & 2032
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe thrombus treatment market accounts for the second-largest market share owing to growing research and treatment of deep-vein thrombosis and growing awareness regarding thrombus complications are the major factors driving the market growth in Europe. For instance, according to the article published in National Center for Biotechnology Information (NCBI), deep vein thrombosis (DVT) is a healthcare burden in Europe. Furthermore, the Germany market of thrombus treatment held the largest market share, and the UK market of thrombus treatment is the fastest growing market in the Europe region.
The Asia-Pacific thrombus treatment market is expected to grow at a significant share from 2024 to 2032. Owing to the presence of a diversified patient pool, the rising prevalence of deep vein thrombosis, and increasing awareness about the treatment and usage of drugs to treat different thrombosis events in countries such as China and India are likely to boost the market in the Asia-Pacific region. Moreover, China market of thrombus treatment held the largest market share, and the India market of thrombus treatment is the fastest growing market in the Asia-Pacific region.
Thrombus Treatment Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the thrombus treatment market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the thrombus treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Teva Pharmaceutical Industries Ltd. (Israel) is one of the leaders in the pharmaceutical industry engaged in developing and providing services for generic medicines. The company utilizes its arrangement of more than 1,800 molecules to create a wide variety of generic products in almost every therapeutic area. It specializes in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women's health, and biologics. In June 2022, the company launched a generic version of apixaban oral anticoagulant that directly inhibits factor X, in UK.
Key Companies in the Thrombus Treatment Market Includes
- Teva Pharmaceutical Industries Ltd. (Israel)
- AngioDynamics Inc. (US)
- Bristol-Myers Squibb Company (US)
- Pfizer Inc. (US)
- Johnson & Johnson Services Inc. (US)
- Sanofi S.A. (France)
- Daiichi Sankyo Company, Limited (Tokyo)
- Boehringer Ingelheim International GmbH (Germany)
- Aspen Pharmacare Holdings Limited (US)
- Bayer AG (Germany)
- Others
Thrombus Treatment Industry Developments
December 2021, Johnson & Johnson's (US) subsidiary Janssen Pharmaceutical Companies (Belgium) announced that the US Food and Drug Administration (FDA) had approved its two paediatric indications for XARELTO.
In April 2021, The US Food and Drug Administration has granted AngioDynamics, Inc. (US) 510(k) clearance for its AlphaVac mechanical thrombectomy system. This allows for precise control of clot removal while minimizing patient blood loss. It has expanded the company's thrombus management portfolio, allowing it to serve the thrombectomy market.
April 2018, Bristol-Myers Squibb Company (US) collaborated with Janssen Pharmaceuticals, Inc. (Belgium) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of BMS-986177, an investigational anticoagulant compound being studied for the prevention and treatment of major thrombotic conditions.
Thrombus Treatment Market Segmentation
Thrombus Treatment Type Outlook
- Atrial Thrombus
- Right Atrial Thrombus
- Left Atrial Thrombus
- Venous Thrombus
Thrombus Treatment Treatment Outlook
- Medical Therapy
- Antiplatelets
- Anticoagulants
- Thrombolytics
- Surgery
- Others
Thrombus Treatment Regional Outlook
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
-
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
